Business Wire·Sep 10, 2026, 8:00 PM ET

UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

Investors with losses in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities can contact Kirby McInerney LLP at investigations@kmllp.com to discuss potential rights in a securities fraud class action at no cost.
The deadline for investors to request appointment as lead plaintiff is November 2, 2026, with courts rejecting applications filed after this date.
The class action covers securities purchased during the period from December 29, 2025, through June 29, 2026.
The lawsuit alleges Unicycive failed to disclose that it had not inspected or audited its third-party manufacturing vendor's facility for compliance with current good manufacturing practices.
The complaint claims the company lacked a reasonable basis to believe the vendor had resolved FDA-cited deficiencies, creating an undisclosed risk of regulatory delays.
Unicycive is accused of failing to reveal that these issues made it reasonably likely that FDA approval for its kidney disease therapy, oxylanthanum carbonate (OLC), would be delayed.
On June 30, 2026, Unicycive disclosed a second Complete Response Letter from the FDA citing the same third-party manufacturing deficiencies identified in a June 2025 letter.
Following the June 30, 2026 disclosure, Unicycive's stock price fell $3.01, or 39.1%, to close at $4.69 per share.
Kirby McInerney LLP is a New York-based firm specializing in securities litigation that has secured billions of dollars in recoveries for shareholders.